# Morepen Laboratories: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Morepen Laboratories Limited · NSE: MOREPENLAB · BSE: 500288 · Sector: Healthcare

Updated for Q2 FY27 · checked 12 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/morepen-laboratories. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Morepen Laboratories: how the business works", with the page URL.

## In short

Drug companies pay Morepen for medicine ingredients and households buy its glucose meters and test strips; materials take the biggest share, and ₹5.1 of every ₹100 that came in was left as profit in FY26.

- In FY26 medicine ingredients (APIs) were 53.32% of Morepen's consolidated sales, medical devices 33.14%, formulations 9.26% and OTC brands 4.28%.
- Of every ₹100 that came in during FY26, ₹60.6 went on materials, ₹17.5 on other running costs and ₹12.6 on staff (Cityfort calculation).

## Key facts

**What does Morepen Laboratories do?**

Morepen Laboratories Ltd is a pharmaceutical company, incorporated in 1984, with four plants in India and a corporate office in Gurugram. Morepen makes active pharmaceutical ingredients (APIs, the chemicals in medicines that do the work), makes ingredients to order for drug companies, and sells glucose meters, test strips and blood-pressure monitors; its FY26 revenue was ₹1,806 crore. [S1, S8]

**How does Morepen Laboratories make money?**

Morepen Laboratories earns most of its money selling APIs: in FY26 APIs were 53.32% of consolidated sales, medical devices 33.14%, formulations 9.26% and OTC brands 4.28%, the last only until Dr. Morepen Ltd stopped being a subsidiary on 31 Jul 2025. Morepen said contract manufacturing (CDMO) brought in ₹253 crore in Q2 FY27. [S1, S25]

**Who are Morepen Laboratories' customers?**

Morepen Laboratories sells APIs to drug makers in India and abroad and names Sandoz, Perrigo and Adamed among its API customers; it also sells glucose meters, test strips and blood-pressure monitors for home use. In FY26 India gave 55.4% of Morepen's consolidated sales and exports 44.6% (Cityfort calculation from the FY26 annual report). [S1]

**How big is Morepen Laboratories?**

In FY26 Morepen Laboratories earned ₹1,806 crore of revenue and ₹94.9 crore of net profit, against ₹1,812 crore and ₹118.0 crore in FY25; FY26 profit included a ₹25.8 crore one-time gain. Morepen had 1,919 permanent employees and workers on 31 Mar 2026. [S8, S12, S1]

**Who owns Morepen Laboratories?**

On 30 Sep 2026 the promoter group held 35.65% of Morepen Laboratories, with no shares pledged. Foreign portfolio investors held 3.43%, Indian institutions 1.71% and other shareholders, mostly individuals and companies, 59.21%. [S34]

**How did Morepen Laboratories do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Morepen Laboratories' revenue was ₹747 crore, up 81.4% from ₹412 crore in Q2 FY26, and net profit was ₹88.9 crore, up 117.5% from ₹40.9 crore; Q2 FY26 profit included a ₹25.8 crore one-time gain. [S6, S10, S21]

**What happened to Dr. Morepen?**

Morepen Laboratories' holding in Dr. Morepen Ltd, which owns OTC brands such as Burnol, fell to 19.94% on 31 Jul 2025, so Dr. Morepen stopped being a subsidiary. Morepen booked a ₹25.8 crore one-time gain in Q2 FY26, and OTC brands were 4.28% of its FY26 consolidated sales. [S1, S21]

**Does Morepen Laboratories have debt?**

Morepen Laboratories had ₹305 crore of borrowings on 30 Sep 2026, up from ₹195 crore on 31 Mar 2026, and ₹271 crore of cash, bank balances and current investments. Infomerics rated its bank facilities IVR A- (Stable) on 22 Aug 2025. [S6, S8, S32]

**What dividend does Morepen Laboratories pay?**

Morepen Laboratories declared a dividend of ₹0.20 a share for FY25 and, at the 26 Sep 2026 AGM, ₹0.20 a share for FY26. The FY25 dividend, paid in FY26, came to ₹10.9 crore. [S1, S55]

## What does Morepen Laboratories sell?

Morepen makes the chemical ingredients that go into medicines and sells them to drug companies. It also makes ingredients to order for other drug companies (CDMO orders), and sells glucose meters, test strips and blood-pressure monitors for use at home.

- **Medicine ingredients (APIs):** Active pharmaceutical ingredients (APIs), the chemicals in a medicine that do the work, such as Loratadine, Montelukast, Desloratadine, Fexofenadine, Atorvastatin and Rosuvastatin. The API business sold ₹983 crore in FY26. Newer molecules such as Edoxaban and Linagliptin brought in ₹56.4 crore, up from ₹25.5 crore in FY25. [S1]
- **Contract manufacturing (CDMO):** CDMO means making ingredients to order for another drug company. In Feb 2026 Morepen won an order worth about ₹825 crore from an unnamed global pharma company. Morepen said CDMO brought in ₹58 crore in Q1 FY27 and ₹253 crore in Q2 FY27. [S47, S26, S25]
- **Home medical devices:** Glucose meters and test strips for people with diabetes, and blood-pressure monitors. The business sold ₹597 crore in FY26, up 20.13%; glucose monitoring was ₹459 crore of it. Morepen says about 20 million of its glucose meters are in use, and it sells about 500 million strips a year. [S1, S25]
- **Finished medicines (formulations):** Tablets and other medicines made for other companies (₹84.9 crore in FY26), branded prescription medicines through Morepen Rx (₹54.5 crore) and supplies to institutions (₹48.3 crore). [S1]

## Who pays Morepen Laboratories?

- **Drug makers buying APIs (53.32% of revenue):** Medicine makers in India and abroad buy Morepen's APIs; Morepen names Sandoz, Perrigo and Adamed among its customers. APIs were 53.32% of FY26 consolidated sales. CDMO orders from drug companies added revenue after FY26. [S1, S25]
- **Households buying medical devices (33.14% of revenue):** People who check their blood sugar or blood pressure at home buy Morepen's meters, test strips and monitors. Devices were 33.14% of FY26 consolidated sales. [S1]
- **Formulation buyers (9.26% of revenue):** Companies that hire Morepen to make their medicines, doctors' prescriptions of Morepen Rx brands, and institutions. Formulations were 9.26% of FY26 consolidated sales. [S1]
- **OTC brand buyers (until 31 Jul 2025) (4.28% of revenue):** Shoppers buying Dr. Morepen's over-the-counter brands, counted only for the four months before Dr. Morepen stopped being a subsidiary. OTC was 4.28% of FY26 consolidated sales. [S1]
- **Customer concentration:** Morepen does not disclose its largest customers' share of sales. Infomerics said in Aug 2025 that Loratadine, Desloratadine and Montelukast together gave around 45–60% of API revenue. The ₹825 crore CDMO order comes from one unnamed company. [S32, S47]

## Where the money went (FY26)

1. In FY26 Morepen sold ₹1,806 crore of goods and earned ₹21.3 crore of other income, plus a ₹25.8 crore one-time gain on Dr. Morepen.
2. Materials and goods bought for resale took ₹1,123 crore, the biggest cost.
3. Employees took ₹233 crore and other running costs ₹324 crore.
4. Depreciation and interest took ₹52.8 crore, income tax ₹24.3 crore and minority holders ₹0.8 crore.
5. What was left was ₹94.9 crore of net profit for Morepen's shareholders.

Sources: S8, S1, S21.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 (restated) | 1,546.8 | 136.7 | 8.8% | 101.7 | 6.6% | 2.26 | −60.2 | 67.4 | −127.6 | S19, S4 |
| FY23 | 1,417.5 | 79.5 | 5.6% | 38.7 | 2.7% | 0.77 | −91.2 | 46 | −137.1 | S18, S4 |
| FY24 | 1,690.4 | 158.6 | 9.4% | 96.2 | 5.7% | 1.88 | 73.4 | 81.3 | −8 | S16, S3 |
| FY25 | 1,811.6 | 174.1 | 9.6% | 118 | 6.5% | 2.2 | 32.1 | 214.2 | −182.2 | S12, S2 |
| FY26 | 1,805.7 | 151.5 | 8.4% | 94.9 | 5.3% | 1.73 | 32.6 | 160.5 | −127.9 | S8, S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 borrowings of ₹305 crore were ₹34.0 crore more than cash, bank balances and current investments of ₹271 crore (Cityfort calculation from the Q2 FY27 results). [S6, S16, S8, S1, S5, S50, S23]

| Item | Value |
| --- | --- |
| Total debt | 305 |
| Cash and investments | 270.9 |
| Net debt (debt minus cash) | 34 |
| Net worth (shareholders' money) | 1,381.1 |
| Debt to equity (times) | 0.22 |

- Borrowings rose from ₹29.0 crore on 31 Mar 2024 to ₹194.7 crore on 31 Mar 2026 and ₹305 crore on 30 Sep 2026. They exclude lease liabilities (₹13.2 crore on 31 Mar 2026).
- Unsecured term loans were ₹134.1 crore on 31 Mar 2026; in FY26 Kookmin, Woori and Hana banks lent ₹130 crore of three-year term loans. The unsecured loans carry the personal guarantee of chairman Sushil Suri.
- In H1 FY27 operating cash flow was ₹127.5 crore and capital spending ₹89.7 crore, leaving ₹37.8 crore of free cash flow (Cityfort calculation).
- The Himachal Pradesh High Court quashed a ₹117.94 crore CGST show-cause notice on 12 Oct 2026; the company said the related ₹317.37 crore contingent liability, including interest and penalty, no longer exists. The filing does not discuss an appeal.
- Debt to equity = borrowings ÷ equity of ₹1,381 crore (Cityfort calculation); the company's own Q2 FY27 presentation gives 0.23x.

## Who owns Morepen Laboratories? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 35.65% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 3.43% |
| Indian institutions (DII) | 1.71% |
| Public | 59.21% |

Sources: S46, S45, S44, S42, S41, S40, S39, S38, S37, S36, S35, S34.

## What could go wrong

### Devices business moving to a subsidiary

Medical devices, 33.14% of FY26 consolidated sales, are to move into Morepen Medipath, 51% owned by Morepen; promoter-group entities and relatives hold 42.89%. Public institutions voted 99.37% against extending the transfer timeline; the resolution passed with 87.49% of votes cast, and the promoter group did not vote. [S1, S20, S51, S55]

What to watch: Completion of the transfer and the final consideration, in exchange filings.

### One large contract order

The ₹825 crore CDMO order comes from one unnamed company and was to be executed over about 12–15 months. Morepen said CDMO brought in ₹253 crore in Q2 FY27, 52% of API plus CDMO revenue. [S47, S25]

What to watch: CDMO revenue each quarter and any new orders filed with the exchanges.

### Price competition in older APIs

Infomerics said average API realisation fell from ₹21,886 in FY24 to ₹20,111 in FY25, and about 24% per kg over two years, as Chinese competitors cut prices in Loratadine, Montelukast and Desloratadine. [S32, S25]

What to watch: Newer molecules' share of API revenue (25% in H1 FY27, company figure).

### Cash flow and rising borrowings

Free cash flow was below zero in every year from FY22 to FY26 (Cityfort calculation). Borrowings rose from ₹29.0 crore in Mar 2024 to ₹305 crore in Sep 2026, and the unsecured term loans carry the chairman's personal guarantee. [S16, S8, S6, S1]

What to watch: Operating cash flow against capital spending, and borrowings, in each half-year filing.

### Exchange surveillance

NSE's surveillance list of 12 Nov 2026 shows Morepen in Long Term ASM Stage IV, and its shares have traded in the trade-for-trade (BE) series since 13 Oct 2026. [S57, S58]

What to watch: NSE's ASM list and the series the shares trade in.

### Pending legal cases

SEBI's appeal in the GDR matter and Morepen's section 408 appeal are pending in the Supreme Court. Two Companies Act prosecutions and nine revision applications are pending in court. [S1]

What to watch: Court outcomes reported in the annual report or exchange filings.

### Currency moves

Exports were 44.6% of FY26 consolidated sales (Cityfort calculation), and Morepen said they were about half of sales in H1 FY27. [S1, S25]

What to watch: The rupee against the US dollar and the export share in each results release.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Devices transfer:** Whether the move of the medical devices business into the 51%-owned Medipath completes, and at what final consideration (₹197.10 crore before adjustments).
- **CDMO after the big order:** CDMO revenue was ₹253 crore in Q2 FY27; the ₹825 crore order was to run for about 12–15 months from the date of award (23 Feb 2026).
- **Debt and cash flow:** Borrowings were ₹305 crore on 30 Sep 2026, and H1 FY27 free cash flow was ₹37.8 crore after five years below zero.

## Sources

- S1: Annual Report FY26 (41st), incl. BRSR FY26. Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_31081_MOREPENLAB_2025_2026_A_7425141_02092026134748.pdf (published 2 Sep 2026)
- S2: Annual Report FY25 (40th). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_27396_MOREPENLAB_2024_2025_A_12082025165430.pdf (published 12 Aug 2025)
- S3: Annual Report FY24 (39th). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_25672_MOREPENLAB_2023_2024_0409202415585.pdf (published 4 Sep 2024)
- S4: Annual Report FY23 (38th) (NSE zip). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_23437_MOREPENLAB_2022_2023_04092023194014_09042023200014.zip (published 4 Sep 2023)
- S5: Q2 FY27 results (standalone + consolidated, unaudited). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_27102026133045_SEIntimationQ2Results271026F.pdf (published 27 Oct 2026)
- S6: Q2 FY27 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1747091_27102026063922_WEB.xml (published 27 Oct 2026)
- S7: Q1 FY27 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1707565_04082026042007_WEB.xml (published 4 Aug 2026)
- S8: Q4 FY26 and FY26 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1673338_26052026064418_WEB.xml (published 26 May 2026)
- S9: Q3 FY26 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1622449_10022026042420_WEB.xml (published 10 Feb 2026)
- S10: Q2 FY26 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1575040_14112025045925_WEB.xml (published 14 Nov 2025)
- S11: Q1 FY26 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1504159_06082025053325_WEB.xml (published 6 Aug 2025)
- S12: Q4 FY25 and FY25 (revised filing) consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1436700_12052025084141_WEB.xml (published 12 May 2025)
- S13: Q3 FY25 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_118928_1373531_06022025065109.xml (published 6 Feb 2025)
- S14: Q2 FY25 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_114921_1304488_11112024064108.xml (published 11 Nov 2024)
- S15: Q1 FY25 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_111459_1221473_12082024053447.xml (published 12 Aug 2024)
- S16: Q4 FY24 and FY24 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_106565_1132278_21052024071814.xml (published 21 May 2024)
- S17: Q3 FY24 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_101900_1040640_31012024062646.xml (published 31 Jan 2024)
- S18: Q4 FY23 and FY23 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_91821_844117_16052023091034.xml (published 16 May 2023)
- S19: Q4 FY22 and FY22 consolidated results (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_83998_651383_05052022090409_WEB.xml (published 5 May 2022)
- S20: Q4 FY26 and FY26 audited results; BTA second addendum (Reg. 30). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_26052026172417_SEIntimation26526V2.pdf (published 26 May 2026)
- S21: Q2 FY26 results (exceptional item note). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_14112025151605_SEResults141125.pdf (published 14 Nov 2025)
- S23: Investor presentation Q2 and H1 FY27. Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_27102026134535_SEIntimationIP271026.pdf (published 27 Oct 2026)
- S25: Press release: Q2 FY27 results. Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_27102026134742_SEIntimationPR271026.pdf (published 27 Oct 2026)
- S26: Press release: Q1 FY27 results. Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_04082026140622_SEIntimationPR4826F.pdf (published 4 Aug 2026)
- S27: Press release: Q4 FY26 results (standalone headline figures). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_27052026080413_PRSEintimation27526.pdf (published 27 May 2026)
- S28: Earnings call transcript Q4 FY25 (call 13 May 2025). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_17052025182913_SEIntimation17525F.pdf (published 17 May 2025)
- S29: Earnings call transcript Q3 FY25 (call 6 Feb 2025). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_12022025133723_SEIntimation12225.pdf (published 12 Feb 2025)
- S30: Earnings call transcript Q2 FY25 (call 12 Nov 2024). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_19112024153210_SEIntimationTRASCRIPT191124.pdf (published 19 Nov 2024)
- S32: Infomerics rating rationale: IVR A-/Stable, long-term bank facilities Rs 225 cr. Infomerics Valuation and Rating Ltd. https://infomericstorage.blob.core.windows.net/uploads/pr_morepen_laboratories_22aug25_e5edef1196.pdf (published 22 Aug 2025)
- S33: Credit rating intimation (Infomerics IVR A-/Stable). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_22082025170753_Draft-SEIntimation.pdf (published 22 Aug 2025)
- S34: Shareholding pattern as of 2026-09-30 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1733884_07102026052649_WEB.xml (published 7 Oct 2026)
- S35: Shareholding pattern as of 2026-06-30 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1691578_13072026052444_WEB.xml (published 13 Jul 2026)
- S36: Shareholding pattern as of 2026-03-31 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1648754_10042026040736_WEB.xml (published 10 Apr 2026)
- S37: Shareholding pattern as of 2025-12-31 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1599549_13012026014919_WEB.xml (published 13 Jan 2026)
- S38: Shareholding pattern as of 2025-09-30 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1543712_09102025062003_WEB.xml (published 9 Oct 2025)
- S39: Shareholding pattern as of 2025-06-30 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1484702_16072025065808_WEB.xml (published 16 Jul 2025)
- S40: Shareholding pattern as of 2025-03-31 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_196948_1415492_16042025122019_WEB.xml (published 11 Apr 2025)
- S41: Shareholding pattern as of 2024-12-31 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_194900_1415153_15042025064450_WEB.xml (published 16 Jan 2025)
- S42: Shareholding pattern as of 2024-09-30 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_191911_1321897_02122024041742_WEB.xml (published 14 Oct 2024)
- S44: Shareholding pattern as of 2024-06-30 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_190147_1242545_12092024080113_WEB.xml (published 18 Jul 2024)
- S45: Shareholding pattern as of 2024-03-31 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_187813_1100876_19042024033628_WEB.xml (published 19 Apr 2024)
- S46: Shareholding pattern as of 2023-12-31 (XBRL). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_184422_1023655_16012024065759_WEB.xml (published 16 Jan 2024)
- S47: Order intimation: CDMO contract about Rs 825 cr (USD 91 mn) from a global pharma company. Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_23022026174249_Draft-Stock_Exchange_intimation.pdf (published 23 Feb 2026)
- S48: Business update: API/CDMO reactor capacity 535 KL to 614 KL. Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_07092026084840_SEIntimation.pdf (published 7 Sep 2026)
- S49: Press release: US prescription generics launch (Desloratadine tablets); first ANDA (Sitagliptin) filed. Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_09112026085234_SEinPressrelease91126.pdf (published 9 Nov 2026)
- S50: HP High Court quashes CGST show-cause notice (Rs 117.94 cr). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_14102026182108_SEIntimation141026.pdf (published 14 Oct 2026)
- S51: Transfer of 9% of Morepen Medipath Ltd to Mr Anubhav Suri (stake 60% to 51%). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_20052026191235_SEIntimation20526.pdf (published 20 May 2026)
- S53: Dr. Morepen Ltd: warrants converted by related parties, stake 100% to 80%. Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_31032025183156_SEintimation31325.pdf (published 31 Mar 2025)
- S54: QIP allotment: 3,67,84,991 shares at Rs 54.37 (Rs 200 cr). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_05082024221418_SEIntimation5824F.pdf (published 5 Aug 2024)
- S55: 41st AGM e-voting results (26 Sep 2026). Morepen Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/MOREPENLAB_26092026201142_SEIntimation260922026.pdf (published 26 Sep 2026)
- S57: NSE ASM list: MOREPENLAB in Long Term ASM Stage IV (as of 12 Nov 2026). NSE. https://www.nseindia.com/api/reportASM (published 12 Nov 2026)
- S58: NSE security-wise historical data, MOREPENLAB (BE series), close 11 Nov 2026. NSE. https://www.nseindia.com/api/historicalOR/generateSecurityWiseHistoricalData?from=01-10-2026&to=12-11-2026&symbol=MOREPENLAB&type=priceVolumeDeliverable&series=ALL (published 11 Nov 2026)
